Proof Medicure Likely to Get FDA Approval

NIA has just posted a 2 minute 22 second must see video clip of Dr. Phillip Pearl the lead investigator of Medicure (TSXV: MPH)'s MEND-PNPO Phase 3 clinical trial.

After you watch this brief video, you will be 100% convinced that NIA's President has discovered what will become the #1 largest gaining biotech stock of 2027 especially on a risk adjusted basis.

Medicure (TSXV: MPH) has the most upside potential relative to very limited downside risk in the biotech sector. We won't be discussing it too much in the weeks ahead because we are all hoping for one last dip to accumulate cheap shares before it begins breaking out into double-digit territory.

Watch the video below of Dr. Phillip Pearl who besides being Medicure (TSXV: MPH)'s lead investigator for their MEND-PNPO Phase 3 clinical trial is also Director of Epilepsy and Clinical Neurophysiology at Boston Children's Hospital and Professor of Neurology at Harvard Medical School.

Anybody who doubts us will regret it!

But go listen to Kevin Bambrough and buy worthless pos Hydrograph Clean Power (CSE: HG) ROFL we're sure you will do well on it lolol!

Full Credit to the Epilepsy Sparks Insights – with Torie Robinson YouTube channel @EpilepsySparksInsights.

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.